Prognostic Role of CRABP2 in Lung Cancer: a Meta-analysis

Overview

Journal J Cardiothorac Surg

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2024 Jun 24

PMID 38915108

Authors

Guang Yang

Qifan Yin

Wenhao Wang

Siwei Xu

Huining Liu

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic value of cellular retinoic acid-binding protein 2 (CRABP2), in lung cancer patients remains to be uncertained. Therefore, our research attempted to assess the relationship between CRABP2 and survival analysis in lung cancer patients through meta-analysis.

Method: Related literature retrieved from Cochrane Library, Ovid, Embase, PubMed, the CNKI, and the Web of Science. The latest update of the search was May 1, 2023. The outcome indicators included as effective measures in the study were hazard ratio (HR), and 95% confidence interval (CI). The Stata 12.0 software was used to analyze the data.

Results: A total of4 studies were finally enrolled in our meta-analysis. The increased plasma level of CRABP2 predicted poor OS in lung cancer patient with a combined HR of 1.14 (95% CI: 1.00-1.30), and were not associated with poor PFS with combined HR: 1.15% CI: 0.63-2.09) in lung cancer patients.

Conclusions: Our meta-analysis found the increased plasma level of CRABP2 was associated with poor OS independently in NSCLC patients. The plasma CRABP2 level may be an indicator of biological aggressiveness of the tumor. Our research was promising regarding the feasibility and utility of plasma CRABP2 as a novel prognostic biomarker in NSCLC, and the findings warrant further investigation.

References

Ye L, Liu R, Lin P, Wang W . Krüppel-like transcription factor 16 transcriptional up-regulation of cellular retinoic acid-binding proteins-2 promotes the invasion and migration and inhibits apoptosis of retinoblastoma cells by regulating integrin-β1/focal adhesion kinase.... Bioengineered. 2022; 13(2):3694-3706. PMC: 8973949. DOI: 10.1080/21655979.2021.2024977. View

Jenkins R, Walker J, Roy U . 2022 cancer statistics: Focus on lung cancer. Future Oncol. 2023; :1-11. DOI: 10.2217/fon-2022-1214. View

Arellano-Ortiz A, Salcedo-Vargas M, Vargas-Requena C, Lopez-Diaz J, de la Mora-Covarrubias A, Silva-Espinoza J . DNA Methylation of Cellular Retinoic Acid-Binding Proteins in Cervical Cancer. Genet Epigenet. 2016; 8:53-57. PMC: 5106192. DOI: 10.4137/GEG.S40847. View

Campos B, Centner F, Lorenzo Bermejo J, Ali R, Dorsch K, Wan F . Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas. Am J Pathol. 2011; 178(5):1953-64. PMC: 3081142. DOI: 10.1016/j.ajpath.2011.01.051. View

Kim D, Kim W, Lim M, Hong Y, Lee S, Hong S . Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer. J Korean Med Sci. 2018; 33(26):e178. PMC: 6010740. DOI: 10.3346/jkms.2018.33.e178. View

Ni M, Shi X, Qu Z, Jiang H, Chen Z, Hu J . Epithelial mesenchymal transition of non-small-cell lung cancer cells A549 induced by SPHK1. Asian Pac J Trop Med. 2015; 8(2):142-6. DOI: 10.1016/S1995-7645(14)60305-9. View

Yi Q, Miao Y, Kong Y, Xu Y, Zhou J, Dong Q . MiR-579 Inhibits Lung Adenocarcinoma Cell Proliferation and Metastasis via Binding to CRABP2. Comput Math Methods Med. 2022; 2022:9111681. PMC: 9371869. DOI: 10.1155/2022/9111681. View

Hui L, Zhang S, Wudu M, Ren H, Xu Y, Zhang Q . CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion. Thorac Cancer. 2019; 10(6):1479-1488. PMC: 6558451. DOI: 10.1111/1759-7714.13097. View

Han S, Kim W, Hong Y, Hong S, Lee S, Ryu D . RNA sequencing identifies novel markers of non-small cell lung cancer. Lung Cancer. 2014; 84(3):229-35. DOI: 10.1016/j.lungcan.2014.03.018. View

10.

Ni X, Hu G, Cai X . The success and the challenge of all-trans retinoic acid in the treatment of cancer. Crit Rev Food Sci Nutr. 2018; 59(sup1):S71-S80. DOI: 10.1080/10408398.2018.1509201. View

11.

Wiener R, Gould M, Arenberg D, Au D, Fennig K, Lamb C . An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice. Am J Respir Crit Care Med. 2015; 192(7):881-91. PMC: 4613898. DOI: 10.1164/rccm.201508-1671ST. View

12.

Meng J, Luo M . CRABP2 involvement in a mechanism of Golgi stress and tumor dry matter in non-small cell lung cancer cells via ER dependent Hippo pathway. Acta Biochim Pol. 2021; 69(1):31-36. DOI: 10.18388/abp.2020_5543. View

13.

Codreanu S, Hoeksema M, Slebos R, Zimmerman L, Rahman S, Li M . Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma. J Proteome Res. 2017; 16(9):3266-3276. PMC: 6339813. DOI: 10.1021/acs.jproteome.7b00245. View

14.

Honecker F, Rohlfing T, Harder S, Braig M, Gillis A, Glaesener S . Proteome analysis of the effects of all-trans retinoic acid on human germ cell tumor cell lines. J Proteomics. 2013; 96:300-13. DOI: 10.1016/j.jprot.2013.11.010. View

15.

Wu J, Lin Y, Tseng C, Chen H, Wang L . Crabp2 Promotes Metastasis of Lung Cancer Cells via HuR and Integrin β1/FAK/ERK Signaling. Sci Rep. 2019; 9(1):845. PMC: 6351595. DOI: 10.1038/s41598-018-37443-4. View

16.

Chen Q, Tan L, Jin Z, Liu Y, Zhang Z . Downregulation of CRABP2 Inhibit the Tumorigenesis of Hepatocellular Carcinoma In Vivo and In Vitro. Biomed Res Int. 2020; 2020:3098327. PMC: 7334762. DOI: 10.1155/2020/3098327. View

17.

Liu C, Hsu Y, Kuo C, Jhuang J, Li Y, Cheng S . CRABP2 Is Associated With Thyroid Cancer Recurrence and Promotes Invasion via the Integrin/FAK/AKT Pathway. Endocrinology. 2022; 163(12). DOI: 10.1210/endocr/bqac171. View

18.

Calmon M, Rodrigues R, Kaneto C, Moura R, Silva S, Mota L . Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia. 2009; 11(12):1329-39. PMC: 2794514. DOI: 10.1593/neo.91110. View

19.

Geiger T, Madden S, Gallagher W, Cox J, Mann M . Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res. 2012; 72(9):2428-39. DOI: 10.1158/0008-5472.CAN-11-3711. View

20.

He J, Yu L, Wang C, Zhou X . MiR-1275 promotes non-small cell lung cancer cell proliferation and metastasis by regulating LZTS3 expression. Eur Rev Med Pharmacol Sci. 2022; 26(7):2215. DOI: 10.26355/eurrev_202204_28445. View